Spiro [1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists [1]

Journal of Medicinal Chemistry

Volumn 41, Issue 13, 1998, Pages 2175-2179

  Yang, Lihu ^a   Guo, Liangqin ^a   Pasternak, Alexander ^a   Mosley, Ralph ^a   Rohrer, Susan ^a   Birzin, Elizabeth ^a   Foor, Forrest ^a   Cheng, Kang ^a   Schaeffer, James ^a   Patchett, Arthur A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[SPIRO(1H INDENE 1,4' PIPERIDIN) 1' YLCARBONYL)AMINO] N (3 AMINOMETHYL 1 CYCLOHEXYLMETHYL) 3 (1H INDOL 3 YL)PROPANAMIDE; OCTREOTIDE; PIPERIDINE DERIVATIVE; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DERIVATIZATION; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; GROWTH HORMONE RELEASE; LETTER; NEUROTRANSMITTER RELEASE; NONHUMAN;

ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CYCLIC AMP; GROWTH HORMONE; HUMANS; INDOLES; LIGANDS; MICE; MODELS, MOLECULAR; PIPERIDINES; PITUITARY GLAND; RATS; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15444348498     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980194h     Document Type: Letter

References (40)

1. Reichlin, S. Somatostatin. N. Engl. J. Med. 1983, 309, 1495-1501.
2. (a) Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Bucher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of the immunoreactive growth hormone. Science 1973, 179, 77-79.
3. (b) Gerich, J. E.; Lovinger, R.; Grodsky, G. M. Inhibition by somatostatin of glucagon and insulin release from the perfused rat pancreas in response to arginine, isoproterenol and theophylline: evidence for a preferential effect on glucagon secretion. Endocrinology 1975, 96, 749-754.
4. (c) Johansson, C.; Wisen, O.; Efendic, S.; Uvnas-Wallensten, K. Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 1981, 22, 126-137.
5. (d) Lamberts, S. W. J.; Krenning, E. P.; Reubi, J.-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev. 1991, 12, 450-482.
6. (a) Gillies, G. Somatostatin: the neuroendocrine story. Trends Pharmacol. Sci. 1997, 18, 87-95.
7. (b) Dournaud, P.; Jazat-Poindessous, F.; Slama, A.; Lamour, Y.; Epelbaum, J. Correlations between water maze performance and cortical somatostatin mRNA and high-affinity binding sites during aging in rats. Eur. J. Neurosci. 1996, 8, 476-485.
8. Recommendations for nomenclature of somatostatin receptors by the following article are adopted in this paper: Hoyer, D.; Bell, G. I.; Berelowitz, M.; Epelbaum, J.; Feniuk, W.; Humphrey, P. P.; O'Carroll, A. M.; Patel, Y. C.; Schonbrunn, A.; Taylor, J. E.; Reisine, T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995, 16, 86-88.
9. (a) Bell, G. I.; Reisine, T. Molecular biology of somatostatin receptors. Trends Neurosci. 1993, 16, 34-8.
10. (b) Yamada, Y.; Post, S.; Wang, K.; Tager, H.; Bell, G. I.; Seino, S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney Proc. Natl. 1992, 89, 251-255.
11. (c) Raynor, K.; O'Carroll, A.; Kong, H.; Yasuda, K.; Mahan, L. C.; Bell, G. I.; Reisine, T. Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol. Pharmacol. 1993, 44, 385-392.
12. (d) Bruno, J. F.; Xu, Y.; Song, J.; Berelowitz, M. Molecular cloning and functional expression of a brain-specific somatostatin receptor, Proc. Natl Acad. Sci. U.S.A. 1992, 89, 11151-11155.
13. (e) O'Carroll, A. M.; Lolait, S. J.; Konig, M.; Mahan, L. C. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol. Pharmacol. 1992, 42, 939-946.
14. (a) Raynor, K.; Murphy, W. A.; Coy, D. H.; Taylor, J. E.; Moreau, J. P.; Yasuda, K.; Bell, G. I.; Reisine, T. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol. Pharmacol. 1993, 43, 838-844.
15. (b) Patel, Y. C.; Srikant, C. B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTR 1-5). Endocrinology 1994, 135, 2814-2817.
16. Lloyd, K. C.; Amirmoazzami, S.; Friedik, F.; Chew, P.; Walsh, J. H. Somatostatin inhibits gastrin release and acid secretion by activating sst2 in dogs. Am. J. Physiol. 1997, 272, G1481-G1488.
17. (a) Rossowski, W.; Coy, D. H. Potent inhibitory effects of type four receptor selective somatostatin analog on rat insulin release. Biochem. Biophys. Res. Commun. 1993, 197, 366-371.
18. (b) Rossowski, W.; Coy, D. H. Specific inhibition of rat pancreatic insulin and glucagon release by receptor-selective somatostatin analogues. Biochem. Biophys. Res. Commun. 1994, 205, 341-346.
19. (c) Coy, D. H.; Rossowski, W. J. Somatostatin analogues and multiple receptors: possible physiological roles. Ciba Found. Symp. 1995, 190, 240-252.
20. (a) Davies, R. R.; Turner, S. J.; Alberti, K. G.; Johnston, D. G. Somatostatin analogues in diabetes mellitus. Diabet. Med. 1989, 6, 103-111.
21. (b) Smith, L. E.; Kopchick, J. J.; Chen, W.; Knapp, J.; Kinose, F.; Daley, D.; Foley, E.; Smith, R. G.; Schaeffer, J. M. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276, 1706-1709.
22. Veber, D. F. Design and discovery in the development of peptide analogs. In Peptides, Chemistry and Biology: Proceedings of the 12th American Peptide Symposium; Smith, J. A., Rivier, J. E., Eds.; ESCOM: Leiden, 1992; pp 3-14.
23. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T.; Pless, J. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982, 31, 1133-1140.
24. Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J., Jr.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981, 292, 55-58.
25. (a) Nicolaou, K. C.; Salvino, J. M.; Raynor, K.; Pietranico, S.; Reisine, T.; Freidinger, R. M.; Hirschmann, R. Design and synthesis of a peptidomimetic employing -D-glucose for scaffolding. In Peptides - Chemistry, Structure and Biology: Proceedings of the 11th American Peptide Symposium; Rivier, J. E., Marshall, G. R., Eds.; ESCOM: Leiden, 1990; pp 881-884.
26. (b) Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Leahy, E. M.; Salvino, J.; Arison, B.; Cichy, M. A.; Spoors, P. G.; Shakespeare, W. C.; Sprengeler, P. A.; Hamley, P.; Smith, A. B. III; Reisine, T.; Raynor, K.; Maechler, L.; Donaldson, C.; Vale, W.; Freidinger, R. M.; Cascieri, M. A.; Strader, C. D. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing D-glucose as a novel scaffolding. J. Am. Chem. Soc. 1993, 115, 12550-12568 and references therein,
27. (c) Papageorgiou, C.; Haltiner, R.; Bruns, C.; Petcher, T. J. Design, synthesis, and binding affinity of a nonpeptide mimic of somatostatin. Bioorg. Med. Chem. Lett. 1992, 2, 135-140.
28. Papageorgiou, C.; Borer, X. A non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure. Bioorg. Med. Chem. Lett. 1996, 6, 267-272.
29. 4 selective somatostatin agonist was reported after the completion of the manuscript: Ankersen, M.; Crider, M.; Liu, S.; Ho, B.; Andersen, H. S.; Stidsen, C. Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity J. Am. Chem. Soc. 1998, 120, 1368-1373.
30. For the most recent work, see: Melacini, G.; Zhu, Q.; Ösapay, G.; Goodman, M. A Refined Model for the Somatostatin Pharmacophore: Conformational Analysis of Lanthionine-Sandostatin Analogs. J. Med. Chem. 1997, 40, 2252-2258 and references therein.
31. Freidinger, R. M.; Veber, D. F. Conformationally directed drug design; ACS Symposium Series, No. 251; American Chemical Society: Washington, DC, 1984; pp 169-187.
32. For a preliminary report, see: Mosley, R. T.; Miller, M. D.; Kearsley, S. K.; Prendergast, K.; Underwood, D. J. New lead discovery in drug development. In Computational Medicine, Public Health and Biotechnology (Part I); Witten, M., Ed.; World Scientific Publishing Co., Pty. Ltd.: Singapore, 1995; pp 101-125.
33. Kearsley, S. K.; Underwood, D. J.; Sheridan, R. P.; Miller, M. D. Flexibases: a way to enhance the use of molecular docking methods. J. Comput.-Aided Mol. Des. 1994, 8, 565-582.
34. Chambers, M. S.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Wong, E. H. F. Spiropiperidines as high- affinity, selective σ Ligands. J. Med. Chem. 1992, 35, 2033- 2039.
35. The crystallographic coordinator experimental values have been deposited with Cambridge Crystallographic Database and are also available from the author.
36. i-coupled receptors. Mol. Cell Neurosci. 1991, 2, 331-338.
37. Nutt, R. F.; Saperstein, R.; Veber, D. F. Structural and conformational studies regarding tryptophan in a cyclic hexapeptide somatostatin analog. In Peptides-Structure and Function: Proceedings of the 8th American Peptide Symposium; Hruby, V. J., Rich, D. H., Eds.; Pierce Chemical Co.: Rockford, IL, 1983; pp 345-348.
38. Nutt, R. F.; Curley, P. E.; Pitzenberger, S. M.; Freidinger, R. M.; Saperstein, R.; Veber, D. F. Novel conformationally constrained amino acids as lysine-9 substitutions in somatostatin analogs. In Peptides-Structure and Function: Proceedings of the 9th American Peptide Symposium; Deber, C. M., Hruby, V. J., Kopple, K. D., Eds.; Pierce Chemical Co.: Rockford, IL, 1985; pp 441-444.
39. Unpublished results.
40. Halgren, T. A. Merck Molecular Force Field. I. basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 1996, 77, 490-519.